期刊
DIABETES RESEARCH AND CLINICAL PRACTICE
卷 90, 期 3, 页码 343-351出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.diabres.2010.08.022
关键词
Sulphonylurea; Glibenclamide; Gliclazide; Cancer; Type 2 diabetes
资金
- Research Grants Council [2008.1.043]
- Hong Kong Foundation for Research and Development in Diabetes under Chinese University of Hong Kong
- Bayer
- Daiichi-Sankyo
- Eli-Lilly
- GSK
- Merck
- Pfizer
- Astra Zeneca
- BMS
- Chinese University of Hong Kong
Background: Hyperglycaemia is a risk factor for cancer and some sulphonylureas have anti-oxidant properties. This study examined associations between use of sulphonylureas and cancer. Methods: A consecutive cohort of 6103 Hong Kong Chinese patients with T2DM, free of cancer, was analysed using Cox models. Sulphonylurea usage was defined as use of the drugs at or within 2.5 years before enrolment and/or during follow-up periods. We adjusted for identified risk factors of cancer, use of other drugs, non-linear associations of lipids with cancer and probabilities of use of these drugs at different times and doses where appropriate. Results: During a median of 4.91 years of follow-up, 271 developed cancer. Glibenclamide, gliclazide and glipizide were ever used in 32.5% (n = 1983), 47.8% (n = 2920) and 13.5% (n = 823). After adjustment for covariates, use of gliclazide and glibenclamide was associated with reduced cancer risk in a dose-dependent manner. In addition, there were interactions between metformin and glibenclamide/glipizide use towards lower adjusted cancer risks. Conclusions: In T2DM, use of glibenclamide and gliclazide may be associated with reduced cancer risk. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据